Live
- AP Legislative Council Approves Key Bills
- WhatsApp Update: WhatsApp Rolls Out Group Mentions in Status Updates
- Czech PM, European Council President-elect discuss cooperation, EU priorities
- 47 killed, 22 injured in Israeli airstrikes on Lebanon's Baalbek-Hermel
- Chandrababu Advocates for Balanced Governance and Development in Andhra Pradesh
- Our 6 free services in Delhi pinching rivals: Kejriwal at 'Revadi par Charcha' campaign
- Abu Dhabi T10: Jos Buttler shines in debut, lauds England batters after memorable performances
- BCCI releases dates for IPL 2025 to 2027
- Centre releases Rs 448 crore as grant for rural local bodies in Karnataka
- India and Japan bolster defence ties, explore air domain cooperation
Cipla top loser in Nifty as US FDA issues warning letter
Cipla shares were down by more than 7 per cent on Thursday after the US FDA issued a warning letter pertaining to its Pithampur manufacturing facility.
New Delhi: Cipla shares were down by more than 7 per cent on Thursday after the US FDA issued a warning letter pertaining to its Pithampur manufacturing facility.
Cipla shares were trading at Rs 1,172, down 7.8 per cent.
Cipla said it has received a warning letter dated November 17 from US Food and Drug Administration (FDA) for the routine current Good Manufacturing Practices (cGMP) inspection conducted at our Pithampur manufacturing facility between February 6-17, 2023.
“This Warning Letter summarises contraventions regarding methods or controls followed at the facility which do not conform to the prescribed cGMP regulations and contains directional guidance for necessary corrections,” Cipla said.
“The company will respond to the Warning Letter within the stipulated timelines and work closely with the FDA to address the concerns in a holistic and timely manner to ensure sustained compliance.
"We uphold quality and compliance with utmost importance and remain committed to be compliant with the cGMP quality standards," it added.
